Moleculin Biotech (MBRX) Competitors $0.67 -0.02 (-3.05%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. FBLG, KPTI, LTRN, XLO, ESLA, LVTX, PLUR, SCYX, RANI, and TPSTShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include FibroBiologics (FBLG), Karyopharm Therapeutics (KPTI), Lantern Pharma (LTRN), Xilio Therapeutics (XLO), Estrella Immunopharma (ESLA), LAVA Therapeutics (LVTX), Pluri (PLUR), SCYNEXIS (SCYX), Rani Therapeutics (RANI), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors FibroBiologics Karyopharm Therapeutics Lantern Pharma Xilio Therapeutics Estrella Immunopharma LAVA Therapeutics Pluri SCYNEXIS Rani Therapeutics Tempest Therapeutics Moleculin Biotech (NASDAQ:MBRX) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations. Does the MarketBeat Community favor MBRX or FBLG? Moleculin Biotech received 218 more outperform votes than FibroBiologics when rated by MarketBeat users. However, 93.33% of users gave FibroBiologics an outperform vote while only 49.47% of users gave Moleculin Biotech an outperform vote. CompanyUnderperformOutperformMoleculin BiotechOutperform Votes23249.47% Underperform Votes23750.53% FibroBiologicsOutperform Votes1493.33% Underperform Votes16.67% Which has more volatility & risk, MBRX or FBLG? Moleculin Biotech has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, FibroBiologics has a beta of -0.8, meaning that its stock price is 180% less volatile than the S&P 500. Which has higher earnings and valuation, MBRX or FBLG? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$29.77MN/AN/AFibroBiologicsN/AN/A-$16.49M-$0.21-4.15 Do institutionals & insiders have more ownership in MBRX or FBLG? 15.5% of Moleculin Biotech shares are owned by institutional investors. 1.9% of Moleculin Biotech shares are owned by company insiders. Comparatively, 20.0% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer MBRX or FBLG? In the previous week, Moleculin Biotech had 7 more articles in the media than FibroBiologics. MarketBeat recorded 11 mentions for Moleculin Biotech and 4 mentions for FibroBiologics. Moleculin Biotech's average media sentiment score of 1.02 beat FibroBiologics' score of 0.64 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MBRX or FBLG more profitable? FibroBiologics' return on equity of 0.00% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -157.44% -97.16% FibroBiologics N/A N/A -225.34% Do analysts recommend MBRX or FBLG? Moleculin Biotech presently has a consensus price target of $4.00, indicating a potential upside of 498.35%. FibroBiologics has a consensus price target of $13.00, indicating a potential upside of 1,389.97%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than Moleculin Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryFibroBiologics beats Moleculin Biotech on 8 of the 14 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.44M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7927.2619.97Price / SalesN/A263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book0.066.597.064.69Net Income-$29.77M$144.20M$3.24B$248.14M7 Day Performance-3.13%3.81%2.56%2.39%1 Month Performance-38.10%11.10%8.75%6.06%1 Year Performance-84.53%3.95%31.30%13.57% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech3.336 of 5 stars$0.67-3.0%$4.00+498.4%-83.9%$9.44MN/A0.0020News CoveragePositive NewsAnalyst UpgradeShort Interest ↓Analyst RevisionFBLGFibroBiologics3.2829 of 5 stars$0.94-1.2%$13.00+1,276.0%-88.9%$36.58MN/A-4.5010KPTIKaryopharm Therapeutics4.037 of 5 stars$4.21-6.2%$43.20+926.1%-71.0%$36.37M$142.13M-4.13380LTRNLantern Pharma2.7119 of 5 stars$3.37+1.5%$25.00+641.8%-39.5%$36.35MN/A-1.8920XLOXilio Therapeutics3.553 of 5 stars$0.70flat$4.00+471.4%-38.1%$36.25M$9.27M-0.4170Short Interest ↓Gap DownESLAEstrella Immunopharma2.121 of 5 stars$0.99-7.2%$16.00+1,518.5%+14.3%$35.75MN/A-3.80N/AShort Interest ↑Gap DownLVTXLAVA Therapeutics2.4928 of 5 stars$1.36+3.0%$3.17+132.8%-42.2%$34.72M$4.99M-1.3260Positive NewsPLURPluri2.0682 of 5 stars$4.39-7.6%$12.00+173.3%-20.8%$34.39M$1.03M-0.78150Short Interest ↑Gap DownSCYXSCYNEXIS0.8829 of 5 stars$0.86-6.3%N/A-60.0%$33.56M$2.63M-1.1660Positive NewsRANIRani Therapeutics2.0106 of 5 stars$0.57+2.5%$9.40+1,537.3%-85.7%$33M$1.20M-0.54110TPSTTempest Therapeutics2.5491 of 5 stars$8.95+8.5%$30.00+235.2%-81.5%$32.95MN/A-5.8520News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies FBLG Competitors KPTI Competitors LTRN Competitors XLO Competitors ESLA Competitors LVTX Competitors PLUR Competitors SCYX Competitors RANI Competitors TPST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBRX Stock Free MBRX Stock Alerts